In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Abstract Introduction Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-
acting antiviral (DAA) therapy approved for patients who have previously failed a DAA …

Background & Aims Clinical trials evaluating second-generation direct-acting antiviral
agents (DAAs) have shown excellent rates of sustained virologic response (SVR) and good …

Chronic infection with the hepatitis C virus (HCV) remains a major health problem affecting
approximately 58 million people worldwide. In the era of interferon (IFN)-based regimens …

Today, with the introduction of interferon-free direct-acting antivirals and outstanding
progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection …

Background The availability of direct‐acting antivirals (DAA s) has dramatically changed the
landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for …

The recommendations define the principles of diagnosis and treatment of hepatitis C virus
(HCV) infection according to the latest knowledge. The main goal of the treatment of HCV …

Interferon‐free combinations were registered in 2014 and 2015 for the treatment of chronic
HCV infection. As a result, real‐world experience has been gathered in the last year and this …

Simple Summary Hepatitis C virus (HCV) is the major factor responsible for hepatocellular
carcinoma (HCC). Currently available treatments for HCV infection are short, simple …

BACKGROUND Nearly 290000 patients with chronic hepatitis C die annually from the most
severe complications of the disease. One of them is liver cirrhosis, which occurs in about …